EPHB4: Ephrin type-B receptor 4
Receptor tyrosine kinase which binds promiscuously to transmembrane ephrin-B family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells.
- Drugs that act on it: 3
- Approved: 0
- In phases 1 to 3: 3
- Sponsors: 3
Who is on it, and how far along
Every drug ChEMBL records acting on EPHB4, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 3
| Tesevatinib | Phase 3 | Sanofi | Small molecule | Inhibitor | 0 |
| JI-101 | Phase 2 | Jubilant Innovation Ltd. | Small molecule | Inhibitor | 0 |
| TG100-801 | Phase 2 | TargeGen | Small molecule | Inhibitor | 0 |
- Capillary malformation-arteriovenous malformation syndrome0.84
- Lymphatic malformation 70.74
- Medullary thyroid gland carcinoma0.54
- Abnormality of the cardiovascular system0.53
- Vein of Galen aneurysm0.51
- EPHB4-associated vascular malformation spectrum0.51
- Lymphatic malformation 10.41
- Neoplasm0.40
- Non-small cell lung carcinoma0.40
- Hydrops fetalis0.38
- Thyroid tumor0.37
- Thyroid gland carcinoma0.37
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL5147, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P54760, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets